Cytology Microarray on Cell Block Preparation: A Novel Diagnostic Approach in Fluid Cytology

被引:3
作者
Bandyopadhyay, Arghya [1 ]
Bhattacharyya, Soumi [1 ]
Roy, Shreosee [1 ]
Majumdar, Kaushik [2 ]
Bose, Kaushik [1 ]
Boler, Anup K. [1 ]
机构
[1] Burdwan Med Coll, Dept Pathol, Kalna Rd, Burdwan 713101, W Bengal, India
[2] Maulana Azad Med Coll, Dept Pathol, GB Pant Inst Post Grad Med Educ & Res, Delhi, India
关键词
Cell block; conventional smear; cytology microarray; TISSUE MICROARRAYS; ADENOCARCINOMA; IMMUNOMARKER; TECHNOLOGY; VALIDATION; EXPRESSION; GEFITINIB; CANCER; MOC-31;
D O I
10.4103/JOC.JOC_15_17
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The cytological examination of serous body effusions to diagnose and stage malignancy is well accepted in clinical medicine. Conventional smear (CS) and cell block (CB) study has to be complemented with immunohistochemistry (IHC) for a definitive diagnosis of malignancy and also to differentiate it from reactive mesothelial cells. Cytology microarray (CMA) is a modification of tissue microarray which involves core needle biopsy of multiple cell blocks and embedding it in a single block. Aim: The aim of this study was to assess the effectiveness of IHC technique in CMA for rapid diagnosis of malignancy and to reduce the cost of testing. Materials and Methods: In this study, 82 pleural fluids were collected and subjected to CS and CB study followed by IHC in CMA blocks. Six commonly used antibodies were applied to confirm malignancy and diagnose the primary. Results: Nineteen cases were diagnosed as malignancy by CB method. MOC-31 confirmed adenocarcinoma deposit in 67% cases of which 44% were proved to be of lung primary by TTF1. Conclusions: IHC on CMA blocks of effusion fluids is a very effective technique that can significantly reduce the cost of testing by >70%.
引用
收藏
页码:79 / 83
页数:5
相关论文
共 28 条
[1]  
Aktas S., 2004, Aegean Pathology Journal, V1, P27
[2]   High-throughput microarray technologies: From genomics to clinics [J].
Bubendorf, L .
EUROPEAN UROLOGY, 2001, 40 (02) :231-238
[3]  
DEKKER A, 1978, AM J CLIN PATHOL, V70, P855
[4]   Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins [J].
Fejzo, MS ;
Slamon, DJ .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (05) :1645-1650
[5]   Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].
Fukuoka, M ;
Yano, S ;
Giaccone, G ;
Tamura, T ;
Nakagawa, K ;
Douillard, JY ;
Nishiwaki, Y ;
Vansteenkiste, J ;
Kudoh, S ;
Rischin, D ;
Eek, R ;
Horai, T ;
Noda, K ;
Takata, I ;
Smit, E ;
Averbuch, S ;
Macleod, A ;
Feyereislova, A ;
Dong, RP ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246
[6]   Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors [J].
Hoos, A ;
Urist, MJ ;
Stojadinovic, A ;
Mastorides, S ;
Dudas, ME ;
Leung, DHY ;
Kuo, D ;
Brennan, MF ;
Lewis, JJ ;
Cordon-Cardo, C .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (04) :1245-1251
[7]   Tissue microarray technology for high-throughput molecular profiling of cancer [J].
Kallioniemi, OP ;
Wagner, U ;
Kononen, J ;
Sauter, G .
HUMAN MOLECULAR GENETICS, 2001, 10 (07) :657-662
[8]   Tissue microarrays for high-throughput molecular profiling of tumor specimens [J].
Kononen, J ;
Bubendorf, L ;
Kallioniemi, A ;
Bärlund, M ;
Schraml, P ;
Leighton, S ;
Torhorst, J ;
Mihatsch, MJ ;
Sauter, G ;
Kallioniemi, OP .
NATURE MEDICINE, 1998, 4 (07) :844-847
[9]  
Korbelik J, 2007, CELL ONCOL, V29, P435
[10]   Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial [J].
Kris, MG ;
Natale, RB ;
Herbst, RS ;
Lynch, TJ ;
Prager, D ;
Belani, CP ;
Schiller, JH ;
Kelly, K ;
Spiridonidis, H ;
Sandler, A ;
Albain, KS ;
Cella, D ;
Wolf, MK ;
Averbuch, SD ;
Ochs, JJ ;
Kay, AC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16) :2149-2158